Orbital Sciences

Orbital Therapeutics is a biotechnology company focused on developing a new generation of RNA-based medicines to treat a wide range of human diseases. The company's proprietary platform integrates state-of-the-art RNA technologies, including circular and linear RNA engineering, with advanced delivery mechanisms like lipid nanoparticles (LNPs) and AI-guided design. Its lead program, OTX-201, is an investigational in vivo CAR-T therapy designed to reprogram cells within the body to deplete B cells, offering a potential treatment for autoimmune diseases. Founded by industry veterans from Alnylam and Moderna, the company was acquired by Bristol Myers Squibb in October 2025 to strengthen its cell therapy and RNA portfolio. Orbital aims to enhance the durability and tissue-specific delivery of RNA therapies, addressing unmet needs in oncology, immunology, and beyond.